-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $65

Benzinga·05/21/2025 15:13:36
Listen to the news
Oppenheimer analyst Jay Olson initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $65.